ResultsIQ

ResultsIQ › Latest results › Camlin Fine Sciences Limited

Camlin Fine Sciences Limited Q2 FY27 earnings call summary

NSE: CAMLINFINE · BSE: 532834

Earnings call of 3 Nov 2026, summarised by AI from the filing.

Camlin Fine Sciences' Q2 FY27 EBITDA margin fell to 2.5% and the Board approved a ₹250 cr rights issue, with Q4 FY27 seen at ₹600 cr top line and ₹60 cr plus EBITDA.

Key takeaways

  1. Rights issue Board approved a ₹250 cr rights issue for working capital, with money expected by end of this calendar year.
  2. Q4 outlook Q4 FY27 top line seen at ₹600 cr and EBITDA ₹60 cr plus, the first quarter with liquidity.
  3. Liquidity risk Channel financing and overdue payables cost about 4% of overall cost, around ₹190-200 million a quarter.

Original filing on BSE

Camlin Fine Sciences Limited Q2 FY27 results

As filed: Revenue ₹491 cr (+7% year on year), EBITDA ₹2.2 cr (−93% year on year), PAT −₹29.7 cr, EBITDA margin 0.5% (−672 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹520 cr (+23% year on year), EBITDA ₹9.3 cr (−51% year on year), PAT −₹33.6 cr, EBITDA margin 1.8% (−270 bps). Score 15 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA growth was below it. EBITDA margin fell 270 bps year on year. Profit fell 1835% from last quarter. Share price after the results: −17.5% in 30 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹425 cr (−3% year on year), EBITDA ₹21.2 cr (−64% year on year), PAT ₹86.3 cr (−96% year on year), EBITDA margin 5.0% (−852 bps). Score 27 of 100, Below trend. Revenue and profit before exceptional items growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 852 bps year on year. Revenue fell 7% from last quarter. Share price after the results: +12.2% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹457 cr (+6% year on year), EBITDA ₹22.0 cr (−55% year on year), PAT −₹37.1 cr (−300% year on year), EBITDA margin 4.8% (−650 bps). Score 20 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin fell 650 bps year on year. Share price after the results: −18.1% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹460 cr (+9% year on year), EBITDA ₹33.0 cr (−23% year on year), PAT −₹15.0 cr, EBITDA margin 7.2% (−299 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 299 bps year on year. Share price after the results: −23.6% in 30 days (Nifty 500: −0.8%).
  • Q1 FY26: Revenue ₹424 cr (+7% year on year), EBITDA ₹19.0 cr (+6% year on year), PAT −₹11.0 cr, EBITDA margin 4.5% (−6 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin was flat year on year. Share price after the results: −14.4% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹437 cr (+9% year on year), EBITDA ₹59.0 cr, PAT ₹0.0 cr, EBITDA margin 13.5% (+1,000 bps). Score 70 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 34% of PBT. Share price after the results: +60.5% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹433 cr (+12% year on year), EBITDA ₹49.0 cr (+113% year on year), PAT −₹7.0 cr, EBITDA margin 11.3% (+536 bps). Score 45 of 100, In line with trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 536 bps year on year. Other income 50% of PBT. Tax rate 350%.

Past price moves after results do not indicate future moves. Not a recommendation.

Camlin Fine Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.